| References |
| 1 |
Canadian Pharmacists Association.
|
| 2 |
Cerner Multum, Inc. "Australian Product Information.".
|
| 3 |
Cerner Multum, Inc. "UK Summary of Product Characteristics.".
|
| 4 |
Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8. [PMID: 5794785]
|
| 5 |
Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
|
| 6 |
Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL "Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans." Clin Pharmacol Ther 60 (1996): 543-53. [PMID: 8941027]
|
| 7 |
Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6. [PMID: 6145728]
|
| 8 |
Product Information. Mellaril (thioridazine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
|
| 9 |
EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
|